• Users Online: 656
  • Print this page
  • Email this page
Year : 2022  |  Volume : 6  |  Issue : 2  |  Page : 184-185

Lurasidone-induced tardive dyskinesia

Department of Psychiatry, Government Medical College, Akola, Maharashtra, India

Correspondence Address:
Dr. Shilpa Avinash Telgote
Department of Psychiatry, Government Medical College, Akola - 444 001, Maharashtra
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/aip.aip_91_20

Rights and Permissions

Lurasidone is a novel atypical antipsychotic with additional antidepressant and pro-cognitive properties. The drug has shown good efficacy in treatment of schizophrenia as well as bipolar disorder. It is currently used as monotherapy as well as adjunctive therapy with Lithium or valproate, due to its lower propensity of cardiometabolic side effects and endocrinological adverse effects. Extra pyramidal side effects and akathisia with lurasidone therapy are reported in a minority of patients, but very few instances of tardive dyskinesia with lurasidone therapy are reported so far.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded32    
    Comments [Add]    

Recommend this journal